Dutch Wholesale/ Industry Price Dispute
The Netherlands' largest pharmaceutical wholesaler, OPG, is currently in dispute with a number of drug manufacturers over prices.
The problem arose as an indirect result of the new drug price law (WGP: Marketletter April 8), which took effect on June 1. Since then, wholesalers and manufacturers have had to negotiate an adjustment to the wholesaler's margin. Under the law, there is no longer a difference in prices to the public between drug specialties, generics and parallel imports.
Just before July 1, the day on which the new prices were introduced, Merck Sharp & Dohme said it would be reducing the wholesalers' margin from 17% to 6%, a cut of 40%. OPG responded by announcing the end of its cooperation with MSD, and said it would be reducing the number of MSD products which it is willing to distribute.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze